Abstracts tagged "Quality and vaccines"

Abstract Number: 2504 • 2015 ACR/ARHP Annual Meeting
Zoster Vaccination in Rheumatoid Arthritis Patients: An Unmet Care Gap
Alicia Meadows¹, Carson Maynard², Abraham Tacang³, Jason Brown⁴ and Eric Newman⁵, ¹Rheumatology, Geisinger Health System, Danville, PA, ²Internal Medicine, Geisinger Medical Center, Danville, PA, ³Geisinger Medical Center, Danville, PA, ⁴Henry Hood Center for Clinical Research, Geisinger Health System, Danville, PA, ⁵Department of Rheumatology, Geisinger Medical Center, Danville, PA
Background/Purpose: Reactivation of the varicella zoster virus (shingles) creates a significant burden of healthcare dollars, lost work time, and extended suffering. Rheumatoid Arthritis (RA) and…
Abstract Number: 845 • 2013 ACR/ARHP Annual Meeting
Improving Pneumococcal Vaccination Rate In The Pediatric Rheumatology Clinic
Julia G. Harris^1,2, Kristyn I. Maletta³, Bixiang Ren³ and Judyann C. Olson^1,2, ¹Medical College of Wisconsin, Milwaukee, WI, ²Children's Hospital of Wisconsin, Milwaukee, WI, ³National Outcomes Center, Children's Hospital of Wisconsin, Milwaukee, WI
Background/Purpose: This quality improvement project was conducted to increase pneumococcal vaccination rates in eligible Pediatric Rheumatology Clinic patients. Streptococcus pneumoniae is a leading cause of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].